TITLE

CLINIC ROUNDUP

PUB. DATE
May 2010
SOURCE
BioWorld Today;5/25/2010, Vol. 21 Issue 100, p7
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This section offers news briefs on clinical trials in the biopharmaceutical industry as of May 25, 2010. The Israeli Ministry of Health has given its approval for the Phase II trial of orally administered CF101 in glaucoma by Can-Fite BioPharma Ltd. The Swedish Medical Products Agency has approved the initiation of a Phase I/IIa trial of Lytixar in nasal decolonization of methicillin-resistant Staphylococcus aureus. Synta Pharmaceuticals Corp. disclosed results from the first state of its trial for STA-9090 in patients with non-small-cell lung cancer.
ACCESSION #
50915241

 

Related Articles

  • CLINIC ROUNDUP.  // BioWorld Today;7/15/2009, Vol. 20 Issue 134, p6 

    This section offers news briefs related to several clinical trials. A Phase I/II trial with CF102 for the treatment of hepatitis C virus by Can-Fite BioPharma of Petach Tikva, Israel will begin to enroll patients. Enrollment for the first of two ongoing blinded, placebo-controlled, multicenter,...

  • Dermatology.  // CenterWatch Weekly;4/6/2015, Vol. 19 Issue 13, p9 

    This article discusses the results of a phase II/III trial by pharmaceutical company Can-Fite BioPharma on the efficacy of the drug CF101 in patients with moderate-to-severe plaque psoriasis.

  • CAN-FITE BIOPHARMA INITIATES CF102 TRIAL FOR LIVER CANCER.  // Worldwide Biotech;May2009, Vol. 21 Issue 5, p8 

    This article reports on the plan of Can-Fite BioPharma of Israel to conduct a I/II clinical trial with CF102 for the treatment of liver cancer in 2009. Can-Fite announced that it will start enrolling patients for the clinical trial. The company will investigate the safety and efficacy of CF102...

  • CLINIC ROUNDUP.  // BioWorld Today;5/6/2008, Vol. 19 Issue 88, p4 

    This section offers news briefs on the pharmaceutical industry. Anesiva Inc. has announced the publication of data from a Phase III trial of Zingo powder intradermal injection in "Journal Pediatrics." Can-Fite BioPharma has successfully completed a Phase I trial with its second pipeline drug,...

  • CLINIC ROUNDUP.  // BioWorld Today;4/2/2010, Vol. 21 Issue 63, p7 

    This section offers news briefs on clinical trials including the completion by Can-Fite BioPharma Ltd. of patient recruitment for its Phase 1/II trial of CF102 in the treatment of patients with advanced hepatocellular carcinoma and the initiation by Symphogen A/S of a Phase I/II trial in the U.S.

  • Dry-Eye Phase III Trial Enrolled, OphthaliX 'Wets' Oral Appetite. Osborne, Randy // BioWorld Today;3/19/2013, Vol. 24 Issue 52, p1 

    The article reports that OphthaliX has tackled its first-in-class A3 adenosine receptor agonist CF101 in a 24-week, 236-patient placebo-controlled Phase III trial. It states that serendipity data provided by patients in a rheumatoid arthritis (RA) trial with CF101 led to dry-eye syndrome (DES)...

  • CLINIC ROUNDUP.  // BioWorld Today;4/17/2009, Vol. 20 Issue 73, p5 

    This section offers news briefs on clinical trials within the biotechnology industry. The Israel Ministry of Health and Rabin MC Ethics Committee have approved the Phase I/II trial of Can-Fite BioPharma for CF102 for the treatment of liver cancer. Diamyd Medical AB plans to cut costs by...

  • Can-Fite BioPharma Announces Successful Results of its Phase I/II Liver Cancer Study with its CF102 Drug; the Study Achieved the Primary and secondary Endpoints.  // Biomedical Market Newsletter;1/7/2012, Vol. 21, p1 

    The article presents information on results of phase I/II clinical trials of Can-Fite BioPharma Ltd. drug candidate CF102 for the treatment of hepatocellular carcinoma (HCC). It is mentioned that the study had primarily evaluated the safety profile of long term administration of drug at three...

  • Can-Fite Announces a Promising Interim Analysis Data of Its Phase I/II Liver Cancer Study with the CF102 Drug.  // Biomedical Market Newsletter;5/16/2011, p369 

    The article focuses on the announcement of the Can-Fite BioPharma Ltd.'s promising Phase 1/2 interim analysis data regarding the CF102 drug for the treatment of liver cancer. It mentions that the analysis data showed a favorable safety profile for CF102 in the patient with liver cancer,...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics